BioSpace News Archive

Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc.

SeraCare Life Sciences, part of the LGC Clinical Diagnostics Business Unit and a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today the commercial release of the first ever genomic DNA (gDNA) and formalin-fixed paraffin-embedded (FFPE) reference materials for tumor mutational burden (TMB) measurement by next-generation sequencing (NGS) assays

Syntrix Pharmaceuticals, Inc., a leading innovator of new pain therapy for the broad multi-billion dollar global pain market, today announced that Syntrix’s President and CEO, John Zebala, MD, PhD, will present an overview of desmetramadol and positive first-in-man trial results at the 2019 Pain Management SUMMIT.

The Alzheimer’s Association and The African Methodist Episcopal Church announced a new three-year partnership aimed at educating and engaging more than 2 million U.S.-based AME Church members in the fight against Alzheimer’s.

Arsenal Capital Partners (“Arsenal”), a leading private equity firm investing in specialty industrials and healthcare companies, announced today that it has completed the acquisition of Clariant’s healthcare packaging business.

SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it has received its eighth ANDA approval from the US Food and Drug Administration (FDA).

The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.'s (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) XOSPATA® (gilteritinib) demonstrated significantly longer Overall Survival (OS) than salvage chemotherapy in adult patients with relapsed (disease that has returned) or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation

SignPath Pharma (Salt Lake City UT) today announced the first commercial out-license of its proprietary CorreQT technology platform. SignPath entered into an agreement with Rain Therapeutics (Newark CA), which licenses SignPath’s CorreQT technology for use in conjunction with Rain’s proprietary lead compound, Tarlox® (tarloxotinib,) a potent pan-ErbB inhibitor in development as a treatment in various cancer indications.

America’s Leading Angel Group lets its Angels choose the winner.

With Open Enrollment for individual consumers beginning tomorrow, November 1, Independence Blue Cross will continue to provide a wide range of health plans to meet the needs of the community.